1. Home
  2. COOK vs IMUX Comparison

COOK vs IMUX Comparison

Compare COOK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

SELL

Current Price

$49.53

Market Cap

134.6M

ML Signal

SELL

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$10.67

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
IMUX
Founded
1985
2016
Country
United States
United States
Employees
N/A
66
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.6M
155.8M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
COOK
IMUX
Price
$49.53
$10.67
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$53.00
$36.00
AVG Volume (30 Days)
13.8K
275.8K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
$559,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.51
52 Week High
$86.59
$17.43

Technical Indicators

Market Signals
Indicator
COOK
IMUX
Relative Strength Index (RSI) 35.10 30.68
Support Level $47.15 $0.78
Resistance Level $77.25 $15.82
Average True Range (ATR) 2.41 0.98
MACD 0.12 -0.37
Stochastic Oscillator 14.19 9.23

Price Performance

Historical Comparison
COOK
IMUX

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: